N/A N=25 Respiratory Strength Training in Cardiac Surgical Patients
Cardiovascular Diseases · Thoracic Diseases · Surgery
Primary: Adherence to Respiratory Strength Training — 35750 Repetitions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,420 DirEct Versus VIdeo LaryngosCopE Trial
Acute Respiratory Failure
Primary: Number of Intubations With Successful Intubation on the First Attempt — 600; 504 Participants
N/A N=58 Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
Upper Limb · Pain
Primary: Percentage of Implanted Subjects Who Respond to DTM SCS Therapy at 3-months — 100 percentage of individual responder
N/A N=870 Physiologic Pacing Registry
Bradycardia · Sinus Node Dysfunction · Heart Block
Primary: Physiologic Pacing Implant Success Rate — 768 Participants
N/A N=29 MOBILE Intervention in College Students With Elevated Blood Pressure
Hypertension
Primary: BP Level — 124.0; 118.7; 77.9; 73.7 mm Hg
Phase 3 N=620 Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining Score (NEI Scale) in the Study Eye at Day 57 — -2.3; -1.1 units on a scale
N/A N=160 Prospective Clinical Evaluation of BD Spinal Needles
Analgesia · Anesthesia
Primary: Primary Safety: Incidence of Post-dural Puncture Headache (PDPH). — 2.8 % of subjects with a PDPH
Phase 2 N=231 A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
COVID-19
Primary: Number of Adverse Events as a Measure of Safety and Tolerability — 1; 6; 3 Number of Adverse Events
N/A N=198 Discharge Medication Counseling in Hospitalized Children
Medication Management
Primary: Observed Dosing Accuracy — 3.3; 1.0 percent difference — p=<0.001
Phase 1 N=18 STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS
Healthy Adults
Primary: (Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 7 — 32.27; 46.94; 54.43 nanogram*hour/milliliter…
N/A N=74 Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents
Advanced Cancer · Relapsed Cancer · Refractory Cancer
Primary: Pediatric Quality of Life — 47.6; 50.3; 61.6; 41.5 score on a scale
N/A N=450 Prospective Observational Study of the Power PICC Family of Devices and Accessories
Peripherally Inserted Central Catheter
Primary: Primary Safety: Incidence of Symptomatic Venous Thrombosis in Patients With a Device From the BD PowerPICC Family Used for Both Short- and Long-term Venous Access. — 1.6…
N/A N=89 Preventing Weight Gain and Unhealthy Behaviors in Children
Obesity
Primary: Change in Body Mass Index Z-score — 0.04; -0.14 z-score — p=0.05
N/A N=30 An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families
Hemophilia A With Inhibitor
Primary: Reduction in the Burden of the Condition Including Treatment Burden, Bleed Frequency, Pain, Control, Freedom and Missed Opportunities) — 19; 10; 12; 9 participants
Phase 2 N=15 Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Gastrointestinal Stromal Tumors
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 13; 8; 9; 3 Participants